These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33054727)

  • 1. Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial.
    Hu J; Wan Q; Zhang Y; Zhou J; Li M; Jiang L; Yuan F
    BMC Cardiovasc Disord; 2020 Oct; 20(1):447. PubMed ID: 33054727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-Term Effects of Tolvaptan in Tricuspid Insufficiency Combined with Left Heart Valve Replacement-Caused Volume-Overload Patients: Results of a Prospective Pilot Study.
    Yuan F; Wu Z; Jiang L; Zhou J; Xu L; Liu H; Ma L; Zhai Z; Zhang J
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):211-218. PubMed ID: 30255476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early continuous ultrafiltration in Chinese patients with congestive heart failure (EUC-CHF): study protocol for an open-label registry-based prospective clinical trial.
    Yang Y; Shen C; Lu J; Xu F; Tong J; Jiang J; Fu G
    BMC Cardiovasc Disord; 2019 Nov; 19(1):249. PubMed ID: 31699029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure.
    Morita Y; Endo A; Kagawa Y; Yamaguchi K; Sato H; Ouchi T; Watanabe N; Tanabe K
    Heart Vessels; 2021 Jun; 36(6):836-843. PubMed ID: 33527152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology.
    Ozierański K; Balsam P; Kapłon-Cieślicka A; Tymińska A; Kowalik R; Grabowski M; Peller M; Wancerz A; Marchel M; Crespo-Leiro MG; Maggioni AP; Drożdż J; Filipiak KJ; Opolski G
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):77-86. PubMed ID: 30649675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial.
    Balsam P; Ozierański K; Marchel M; Gawałko M; Niedziela Ł; Tymińska A; Sieradzki B; Sieradzki M; Fojt A; Bakuła E; Główczyńska R; Peller M; Markulis M; Bednarski J; Kowalik R; Cacko A; Niewiński G; Filipiak KJ; Opolski G; Grabowski M
    Cardiol J; 2019; 26(6):661-668. PubMed ID: 31909470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure.
    Sato Y; Uzui H; Mukai M; Shiomi Y; Hasegawa K; Ikeda H; Tama N; Fukuoka Y; Morishita T; Ishida K; Kaseno K; Miyazaki S; Nakano A; Tada H
    J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):47-56. PubMed ID: 31280620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.
    Fukuoka H; Tachibana K; Shinoda Y; Minamisaka T; Inui H; Ueno K; Inoue S; Mine K; Ueda K; Hoshida S
    BMC Cardiovasc Disord; 2020 Oct; 20(1):467. PubMed ID: 33121430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
    Takagi K; Sato N; Ishihara S; Iha H; Kobayashi N; Ito Y; Nohara T; Ohkuma S; Mitsuishi T; Ishizuka A; Shigihara S; Sone M; Nakama K; Tokuyama H; Omote T; Kikuchi A; Nakamura S; Yamamoto E; Ishikawa M; Amitani K; Takahashi N; Maruyama Y; Imura H; Shimizu W
    J Cardiol; 2020 Nov; 76(5):499-505. PubMed ID: 32665162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.
    Niikura H; Iijima R; Anzai H; Kogame N; Fukui R; Takenaka H; Kobayashi N
    Anatol J Cardiol; 2017 Sep; 18(3):206-212. PubMed ID: 28777097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
    Wang C; Xiong B; Cai L
    BMC Cardiovasc Disord; 2017 Jun; 17(1):164. PubMed ID: 28633650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
    Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
    J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
    Matsue Y; Suzuki M; Nagahori W; Yoshida K; Onishi Y; Satoh Y; Ono Y; Nishioka T; Noda M; Sugi K; Torii S; Tejima T; Sakurada H; Yamaguchi S; Okishige K; Fujii H; Takahashi A
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):73-7. PubMed ID: 24048511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance.
    Moranville MP; Choi S; Hogg J; Anderson AS; Rich JD
    Cardiovasc Ther; 2015 Apr; 33(2):42-9. PubMed ID: 25712736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study.
    Rahhal A; Saad MO; Tawengi K; Assi AAR; Habra M; Ahmed D
    BMC Cardiovasc Disord; 2019 May; 19(1):127. PubMed ID: 31138146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y; Inomata T; Kida K; Shibagaki Y; Sato N; Izumi T; Ako J;
    Heart Vessels; 2019 Mar; 34(3):442-451. PubMed ID: 30259172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.